First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration resistant prostate carcinoma

2024-512894-29-00 Protocol PSMAxCD3 Phase I and Phase II (Integrated) - First administration to humans Ongoing, recruiting

Start 15 Nov 2019 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol PSMAxCD3

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ongoing, recruiting
Participants planned 44
Countries 1
Sites 2

Prostate Cancer

Key facts

Sponsor
Universitaetsklinikum Tuebingen AöR
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Male Urogenital Diseases [C12]
Trial duration
15 Nov 2019 → ongoing
Decision date (initial)
2024-04-12
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512894-29-00
EudraCT number
2019-000238-20
ClinicalTrials.gov
NCT04104607

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Prostate Cancer

VersionLevelCodeTermSystem organ class
20.0 LLT 10036910 Prostate cancer NOS 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Tuebingen AöR

Sponsor organisation
Universitaetsklinikum Tuebingen AöR
Address
Geissweg 3, Innenstadt Innenstadt
City
Tuebingen
Postcode
72076
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
KKE Translationale Immunologie

Public contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
KKE Translationale Immunologie

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 44 2
Rest of world 0

Investigational sites

Germany

2 sites · Ongoing, recruiting
Universitaetsklinikum Tuebingen AöR
KKE Translationale Immunologie Tübingen, Otfried-Mueller-Strasse 10, Nordstadt, Tuebingen
Charite Universitaetsmedizin Berlin KöR
Charité Benjamin Franklin Onkologische Studienzentrale, Hindenburgdamm 30, Lichterfelde, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2019-11-15 2019-11-18

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-21 Germany Acceptable
2024-04-04
2024-04-12
2 SUBSTANTIAL MODIFICATION SM-1 2025-08-13 Germany Acceptable
2025-10-13
2025-10-16
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-11-03 Germany Acceptable
2025-10-13
2025-11-03
4 SUBSTANTIAL MODIFICATION SM-2 2025-12-03 Germany Acceptable
2026-02-06
2026-02-11